Five months after a unanimous thumbs-up by a US Food and Drug Administration (FDA) advisory panel, the agency granted its approval July 10, 2009, to the anticlotting agent prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), according to announcements by the FDA and the drug’s manufacturers.

This marks the US approval of the first major competitor to clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) for this indication. Prasugrel (Effient, Daiichi Sankyo/Eli Lilly) brings with it both benefits and risks, as research has shown that while the drug can reduce ....

You must be a member to access this content. To continue reading, please enter your username and password above.

If you have not yet registered, we would like to take this opportunity to welcome you to TCTMD - The Source for Interventional Cardiovascular News & Education.

If you are already a member, please re-enter your username and password above, and then click LOGIN.

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.